Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials
Authors:
- Mable PereiraMPMable Pereira
- Ancy Jenil FrancoAFAncy Jenil Franco
- Karthik ChintharalaKCKarthik Chintharala
- Ana Carolina Putini VieiraAVAna Carolina Putini Vieira
- Ana Carolina Ventura de Santana de JesusAJAna Carolina Ventura de Santana de Jesus
- Paweł ŁajczakPŁPaweł Łajczak
- Khaled AlhwaishelKAKhaled Alhwaishel
- Mario Saul Lira CastañedaMCMario Saul Lira Castañeda
- Elizabet Taylor Pimenta WebaEWElizabet Taylor Pimenta Weba
- Kristian ReichKRKristian Reich
- 15 February 2025
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (3) , 1033-1042
Abstract
Mirikizumab, an interleukin-23 (IL-23) p19 subunit inhibitor, has emerged as a promising treatment for moderate-to-severe plaque psoriasis. Despite its promising results, a comprehensive synthesis of clinical data is essential to assess its overall efficacy and safety profile. We searched PubMed, Embase, and Cochrane for studies assessing mirikizumab in moderate-to-severe psoriasis. A random-effects model using Inverse Variance (IV) computed mean differences (MD) for continuous outcomes and risk ratios (RR) for binary endpoints. Risk Difference (RD) studies were analysed using generic inverse variance (GIV) in Review Manager. Statistical analyses were conducted using R software version 4.2.1, following PRISMA guidelines. This analysis of three RCTs involving 1,649 adult patients over 16-52 weeks demonstrated mirikizumab's significant efficacy in treating psoriasis. At 16 weeks, mirikizumab substantially reduced Body Surface Area (BSA) to < 1% (RR: 34.53, p < 0.001) and improved PASI scores (PASI 100 RR: 25.94, PASI 90 RR: 11.50, PASI 75 RR: 10.47, all p < 0.001). Static Physician's Global Assessment (sPGA) scores of 0/1 were achieved (RR: 12.48, p < 0.001). Quality of life measures also improved significantly, with increases in SF-36 Physical and Mental Component Summaries (MD: 4.02 and 3.53 respectively, p < 0.01) and Dermatology Life Quality Index (DLQI) scores of 0/1 (RD: 0.51, p < 0.00001). Importantly, the safety profile of mirikizumab was comparable to the control, with no significant differences in the overall incidence of adverse effects (RR: 0.97; 95% CI: 0.86-1.10) or in serious adverse effects (RR: 1.61; 95% CI: 0.55-4.73). These results collectively demonstrate the efficacy and safety of mirikizumab in treating psoriasis, with significant improvements across multiple clinical and quality-of-life measures. This meta-analysis demonstrates that mirikizumab significantly reduces psoriasis severity and improves quality of life, with a favourable safety profile. These findings support its use as a valuable treatment option for moderate-to-severe plaque psoriasis. Further research is needed to assess long-term outcomes and comparative effectiveness.Keywords
This publication has 19 references indexed in Scilit:
- Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A ReviewAmerican Journal of Clinical Dermatology, 2021
- Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted TherapiesFrontiers in Immunology, 2021
- Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive ReviewAmerican Journal of Clinical Dermatology, 2020
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative ColitisGastroenterology, 2020
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyJournal of the American Academy of Dermatology, 2019
- Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II studyBritish Journal of Dermatology, 2019
- The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasisJournal of the European Academy of Dermatology and Venereology, 2017
- The cost of applying to dermatology residencyJournal of the American Academy of Dermatology, 2016
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and PrevalenceJournal of Investigative Dermatology, 2013
- Ustekinumab for the treatment of moderate to severe psoriasisHealth Technology Assessment, 2009